Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients

Journal of Infection

Volumn 65, Issue 5, 2012, Pages 439-446

  Grima, Pierfrancesco ^a,b   Fabbiani, Massimiliano ^b   Ciccarelli, Nicoletta ^b   Tana, Mariangela ^a   Farina, Salvatore ^b   Colafigli, Manuela ^b   Mondi, Annalisa ^b   Cauda, Roberto ^b   Di Giambenedetto, Simona ^b  

^a S Caterina Novella Hospital   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cerebrovascular disease; Dementia; HIV associated neurocognitive disorders; Ophthalmic artery resistance index

Indexed keywords

VIRUS RNA;

ADULT; APTITUDE TEST; ARTERY BLOOD FLOW; ARTICLE; CARDIOVASCULAR PARAMETERS; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOENCEPHALOGRAPHY; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; OPHTHALMIC ARTERY; OPHTHALMIC ARTERY RESISTANCE INDEX; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; VASCULAR RESISTANCE;

ADULT; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; HIV INFECTIONS; HUMANS; INTRACRANIAL ARTERIAL DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; OPHTHALMIC ARTERY; REGRESSION ANALYSIS; ROC CURVE;

EID: 84867328279     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.07.005     Document Type: Article

References (47)

1. Sacktor N., Lyles R.H., Skolasky R., Kleeberger C., Selnes O.A., Miller E.N., et al. HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990-1998. Neurology 2001, 56:257-260.
2. McArthur J.C. HIV dementia: an evolving disease. J Neuroimmunol 2004, 157:3-10.
3. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293-299. The Antiretroviral Therapy Cohort Collaboration.
4. Letendre S, FitzSimons C, Ellis R. Correlates of CSF viral loads in 1221 volunteers of the CHARTER cohort, [abstract 172]. Presented at the 17th conference on retrovirus and opportunistic infections; February 16-19, 2010; San Francisco.
5. Ciccarelli N., Fabbiani M., Di Giambenedetto S., Fanti I., Baldonero E., Bracciale L., et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011, 76:1403-1409.
6. Lewden C., May T., Rosenthal E., Burty C., Bonnet F., Costagliola D., et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "mortalitè 2000 and 2005" survey (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008, 48:590-598.
7. Sacktor N., Skolasky R., Selnes O.A., Watters M., Poff P., Shiramizu B., et al. Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals. J Neurovirol 2007, 13:203-209.
8. Grima P., Guido M., Chiavaroli C., Zizza A. Ultrasound-assessed perirenal fat is related to increased ophthalmic artery resistance index in HIV-1 patients. Cardiovasc Ultrasound 2010, 8:24.
9. Hu H.H., Sheng W.Y., Yen M.Y., Lai S.T., Teng M.M. Color doppler imaging of orbital arteries for detection of carotid occlusive diseases. Stroke 1993, 24:1196-1203.
10. Tranquart F., Berges O., Koskas P., Arsene S., Rossazza C., Pisella P.J., et al. Color doppler imaging of orbital vessel: personal experience and literature review. J Clin Ultrasound 2003, 31:258-273.
11. Maruyoshi H., Kojima S., Nagayoshi Y., Horibata Y., Kaikita K., Sugiyama S., et al. Waveform of ophthalmic artery doppler flow predict the severity of systemic atherosclerosis. Circ J 2010, 74:1251-1256.
12. Yamamoto T., Mori K., Yasuhara T., Yokoi N., Kinoshita S., Kamei M. Ophthalmic artery blood flow in patients with internal carotid artery occlusion. Br J Ophtalmol 2000, 88:505-508.
13. Reynolds P.S., Greenberg J.P., Liene L.M., Meads D.C., Myers L.G., Tegeler C.H. Ophthalmic artery flow direction on color flow duplex imaging is highly specific for sever carotid stenosis. J Neuroimaging 2002, 12:5-8.
14. Wendell C.R., Zonderman A.B., Metter E.J., Najjar S.S., Waldstein S.R. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 2009, 40:3180-3185.
15. Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, Di Cristo V, et al. CV Risk factors and carotid IMT are associated to lower neurocognitive performance in HIV-infected patients. HIV Med 2012; in press.
16. Haley A.P., Forman D.E., Poppas A., Hoth K.F., Gunstad J., Jefferson A.L., et al. Carotid artery intima-media thickness and cognition in cardiovascular disease. Int J Cardiol 2007, 121:148-154.
17. Grima P., Guido M., Chiavaroli R., De Donno A., Tana M., Zizza A. Comparison of intima-media thickness and ophthalmic artery resistance index for assessing subclinical atherosclerosis in HIV-1-infected patients. Cardiovasc Ultrasound 2011, 9:9.
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106:3143-3421.
19. Carlesimo G.A., Caltagirone C., Gainotti G. The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The group for the standardization of mental deterioration battery. Eur Neurol 1996, 36:378-384.
20. Orsini A., Grossi D., Capitani E., Laiacona M., Papagno C., Vallar G. Verbal and spatial immediate memory span: normative data from 1355 adults and 1112 children. Ital J Neurol Sci 1987, 8:539-548.
21. Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A. Una versione abbreviata del test di Stroop: dati normativi nella popolazione italiana. Rivista di Neurologia 2002, 12:4.
22. Giovagnoli A.R., Del Pesce M., Mascheroni S., Simoncelli M., Laiacona M., Capitani E. Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 1996, 17:305-309.
23. Jenner C., Reali G., Puopolo M., Silveri M.C. Can cognitive and behavioural disorders differentiate frontal variant-frontotemporal dementia from alzheimer's disease at early stages?. Behav Neurol 2006, 17(2):89-95.
24. Marra C., Gainotti G., Scaricamazza E., Piccininni C., Ferraccioli M., Quaranta D. The multiple features target cancellation (MFTC): an attentional visual conjunction search test. Normative values for the Italian population. Neurol Sci 2012 Feb 19, [Epub ahead of print].
25. Orsini A., Laicardi C., WAIS- R. Contributo alla taratura italiana 1997, Giunti OS, Firenze.
26. Antinori A., Arendt G., Becker J.T., Brew BJ., Byrd DA., Cherner M., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
27. Lindl K.A., Marks D.R., Kolson D.L., Jordan-Sciutto K.L. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol 2010, 5:294-309.
28. Woods S.P., Moore D.J., Weber E., Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009, 19:152-168.
29. Robertson K.R., Smurzynski M., Parsons T.D., Wu K., Bosch R.J., Wu J., et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007, 21:1915-1921.
30. Cysique L.A., Brew B.J. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011, 17:176-183.
31. Smurzynski M., Wu K., Letendre S., Robertson K., Bosch RJ., Clifford DB., et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011, 25:357-365.
32. Giancola M.L., Lorenzini P., Balestra P., Larussa D., Baldini F., Corpolongo A., et al. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 41:332-337.
33. Tozzi V., Balestra P., Bellagamba R., Corpolongo A., Salvatori MF., Visco-Comandini U., et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007, 45:174-182.
34. Heaton R.K., Clifford D.B., Franklin D.R., Woods SP., Ake C., Vaida F., et al. HIV associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010, 75:2087-2096.
35. Becker J.T., Kingsley L., Mullen J., Cohen B., Martin E., Miller E.N., et al. Vascular risk factors, HIV serostatus, and cognitive disfunction in gay and bisexual men. Neurology 2009, 73:1292-1299.
36. Wright E.J., Grund B., Robertson K., Brew BJ., Roediger M., Bain MP., et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010, 75:864-873.
37. Foley J., Effenhofer M., Wright M.J., Siddiqi I., Choi M., Thames A.D., et al. Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol 2010, 24:265-285.
38. Waldstein S.R., Wendell C.R. Neurocognitive function and cardiovascular disease. J Alzheimers Dis 2010, 20:833-842.
39. Dempsey R.J., Vemuganti R., Varghese T., Hermann B.P. A review of carotid atherosclerosis and vascular cognitive decline: a new understanding of the keys to symptomology. Neurosurgery 2010, 67:484-494.
40. Cohen R.A., Poppas A., Forman D.E., Hoth K.F., Haley A.P., Gunstad J., et al. Vascular and cognitive functions associated with cardiovascular disease in the elderly. J Clin Exp Neuropsychol 2009, 31:96-110.
41. Paul R.H., Haque O., Gunstad J., Tate D.F., Grieve S.M., Hoth K., et al. Subcortical hyperintensities impact cognitive function among a select subset of healthy elderly. Arch Clin Neuropsychol 2005, 20:697-704.
42. Cruse B., Cysique L.A., Markus R., Brew B.J. Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. J Neurovirol 2012, 18:264-276.
43. Connor M.D., Lammie G.A., Bell J.L., Warlow C., Simmonds P., Brettle R. Cerebral infarction in adult AIDS patients: observations from the Edimburg HIV autopsy cohort. Stroke 2000, 31:2117-2126.
44. Villenevue S., Belleville S., Massoud F., Bocti C., Gauthier S. Impact of vascular risk factors and diseases on cognition in persons with mild cognitive impairment. Dement Geriatr Cogn Disord 2009, 27:375-381.
45. Mariani E., Monastero R., Ercolani S., Mangialasche F., Caputo M., Feliziani F.T., et al. Vascular risk factors in mild cognitive impairment subtypes. Dement Geriatr Cogn Disord 2007, 24:448-456.
46. Stern R.A., Silva S.G., Chaisson N., Evans D.L. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol 1996, 53:148-153.
47. Sheri M., Shimizu D.C.C., Valcour V., Masaki K., Nakamoto B., Kallianpur K.J., et al. The impact of depressive symptoms on neuropsychological performance tests in HIV-infected individuals: a study of the Hawaii aging with HIV cohort. World J AIDS 2011, 1:139-145.